礼来12亿美元收购Ventyx获NLRP3抑制剂管线;邦耀生物任命向宇为首席执行官丨医药早参

每日经济新闻
Jan 09

丨 2026年1月9日星期五丨  NO.1礼来12亿美元收购Ventyx,获NLRP3抑制剂管线  礼来公司宣布将以每股14美元的全现金交易,收购Ventyx Biosciences,获临床阶段NLRP3抑制剂管线,总股权价值约12亿美元。此次收购溢价高达62%,预计将于2026年上半年完成。  点评:礼来12亿美元溢价62%收购Ventyx,补全炎症领域布局,有望与GLP-1产品形成协同,抢占...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10